Eiken Chemical Co., Ltd. · TSE:4549
Eiken Chemical — FY2010 Earnings Presentation
17 slides from Eiken Chemical's earnings presentation, Apr 28, 2011
Slide 1: Business performance briefing for the term ended Mar. 2011
The business performance briefing for the term ended Mar. 2011 (the 73rd term) (Apr. 2010-Mar. 2011) EIKEN CHEMICAL CO., LTD. Apr. 28, 2011 EIKEN CHEMICAL CO., LTD. 1 Operating Results for the term ended Mar. 2011 (the 73rd term) EIKEN CHEMICAL CO., LTD 1
Slide 2: Consolidated performance for the term ended Mar. 2011
Consolidated performance for the term ended Mar. 2011 (the 73rd term) (Millions of yen) Term ended Mar. 2011 Difference from target value YoY change Target value Actual results Ratio Difference Results Difference Net sales 27,080 27,562 100.0 +482 26,841 +721 Operating income 2,400 2,709 9.8 +309 1,
Slide 3: Consolidated sales for product category
Consolidated sales for product category (Millions of yen) Immunological and Term ended Mar. 2009 Term ended Mar. 2010 Term ended Mar. 2011 serological reagents 8,251 8,626 8,909 8,626 8,909 ● 3.3% increase from the 8,251 corresponding term in the previous year ● The sales of Tosoh corporation’s reag
Slide 4: Consolidated sales for product category: dry and clinical chemistry reagents
Consolidated sales for product category (Millions of yen) Term ended Mar. 2009 Term ended Mar. 2010 Term ended Mar. 2011 Dry chemistry reagents 1,834 1,873 1,948 1,948 1,873 ● 4.0% increase from the 1,834 corresponding term in the previous year ● The sales of urinalysis test trip ”Uropaper α” for th
Slide 5: Consolidated sales for product category: industry products, medical devices
Consolidated sales for product category (Millions of yen) Industry products (Culture Term ended Mar. 2009 Term ended Mar. 2010 Term ended Mar. 2011 media for equipment, food and environment category) 2,678 2,552 2,441 2,678 ● 4.4% decrease from the 2,552 corresponding term in the 2,441 previous year
Slide 6: Consolidated overseas sales
Consolidated overseas sales (Millions of yen) Term ended Mar. 2009 Term ended Mar. 2010 Term ended Mar. 2011 Sales 1,538 1,632 1,689 Ratio of overseas 5.9% 6.1% 6.1% sales OC others 634 559 624 ● 3.5% increase from the corresponding term in the previous year 1,073 1,065 904 Term ended Mar. Term ende
Slide 7: SG&A expenses, gross margin and consolidated balance sheets
Transition in SG&A expenses and gross margin (consolidated) ◆ Gross margin ・ lower manufacturing costs 42.5% 41.7% 40.5% 35.5% 33.4% ▲ Ratio of selling, general and 31.8% administrative expenses ・ Efficient use of the budget Term ended Mar. 2009 Term ended Mar. 2010 Term ended Mar. 2011 EIKEN CHEMIC
Slide 8: Consolidated cash flows
Consolidated cash flows (Millions of yen) Term ended Mar. 2010 Term ended Mar. 2011 Cash and cash equivalents at beginning of the period 5,418 7,037 Net cash provided by (used in) operating activities 2,709 2,212 Net cash provided by (used in) investing activities (660) (4,127) Net cash provided by
Slide 9: Primary strategies for the term ended Mar. 2011
Primary strategies for the term ended Mar. 2011 (the 73rd term) EIKEN CHEMICAL CO., LTD Primary strategies for the term ended Mar. 2011 (the 73rd term) 1. Promotion of the sale measure Japan ・ Promotion of medical devices (to increase the sales of OC, US, and LAMP) ・Promotion of ABC Examination main
Slide 10: Promotion of sales measures; R&D and new products
Primary strategies for the term ended Mar. 2011 (the 73rd term) 1. Promotion of the sale measure Europe ・ OC Screening in France : postponement of the bid time ・ Adoption decision of the OC screening in Austria and Czech ・ Prepare for the establishment of Europe office Asia, etc ・ Expansion of OC sc
Slide 11: FIND business and productivity improvements
Primary strategies for the term ended Mar. 2011 (the 73rd term) 3. FIND business (1) Tuberculosis test [In Japan] June 2011 Launch of “Loopamp® Tuberculosis Complex Detection Reagent Kit” , “Loopamp® PURE DNA Extraction Kit” and “Loopamp® LF- 160 Homeothermal Equipment with Fluorometer” . [Outside J
Slide 12: Return to shareholders (dividend)
Return to shareholders (dividend) ◆ Continuation of stable dividend ・ Term-end dividend: 18 yen per share ・ Consolidated payout ratio: 32.6% The year-end dividend per share in the current fiscal year was 18 yen from the perspective of returning profits and the aim of providing a consolidated dividen
Slide 13: Strategies for the term ending Mar. 2012: sales promotion and global expansion
Primary strategies and earnings forecast for the term ending Mar. 2012 (the 74th term) 1. Sales promotion (1) Domestic market - Strengthening of sales promotion system for our flagship products - Promotion of installation of equipment - Launch and sales promotion of LAMP reagent for tuberculosis tes
Slide 14: R&D strengthening and FIND business for Mar. 2012
Primary strategies and earnings forecast for the term ending Mar. 2012 (the 74th term) 3. Strengthening of research and development (1) Acceleration of product development - Further promotion of the development of LAMP reagent - Promotion of development of new immunological reagents and equipment -
Slide 15: Productivity improvement and consolidated earnings forecast
Primary strategies and earnings forecast for the term ending Mar. 2012 (the 74th term) 5. Improvement in productivity, and reinforcement of the system (1) Improvement of sales cost ratio Reduction of manufacturing costs, etc. (2) Reorganization of the production base Togane Plant closure (scheduled
Slide 16: R&D cost and investment in equipment
R&D cost and investment in equipment (consolidated) R&D cost Investment in equipment Depreciation and amortization (Millions of yen) (Millions of yen) (Millions of yen) 2,348 4,243 1,924 1,884 1,006 922 923 2,155 690 Term ended Term ended Term ended Term ended Term ended Term ended Term ended Term e
Slide 17: Notes
Notes This document is not the disclosed reference for financial instruments and exchange. Its accuracy and integrity are not guaranteed. The estimates, etc. written in this document are based on currently available information, and so actual values may be different due to various factors. This docu